Ronen is the current chair of the technolםgy marketing dept, and was the founder of the BioMed specialty in the dept.
Ronen's passion is connecting theory and practice. On the theory side, Ronen holds a Ph.D. in health systems management from the Ben-Gurion University of the Negev, MBA from the EMBA joint program of Kellogg (Northwestern U.) and Tel-Aviv U. and BSc in industrial engineering from Tel-Aviv U.
On the practical side, Ronen has >30 years of experience in managing innovation, in various high tech and academic institutions.
The focus of Ronen's research is on the evaluation of clinical and economic outcomes of innovative healthcare interventions, primarily cardiovascular medications. For this purpose, a research lab was founded and named Maximizing health Outcomes Research Lab (MaxCor).
To promote lab research, 3 multi-disciplinary research groups were established. The first group includes the research department of Clalit Health Services (CHS), and the hematology center of Meir MC. The group focuses on direct anticoagulant (DOAC) medications. The second group includes the drug evaluation department of CHS and leading physicians in diabetology from CHS and Maccabi Health Services. The group focuses on medications for type 2 diabetes. The third group includes the technology evaluation department in the Ministry of Health (MOH) and top management at a leading hospital. This group focuses on the adoption of innovative technologies in hospitals.
2019 Paul Dudley White International Scholar at the International Stroke Conference held in Honolulu, Hawaii from February 5-9, 2019.
2019 Paul Dudley White International Scholar at the AHA scientific sessions held in Philadelphia, PA on November 16-18 2019.
1. Arbel, R. & Greenberg, D. (2016). Rethinking cost-effectiveness in the era of zero healthcare spending growth. International Journal for Equity in Health, 15, 1-7.
(5-year Impact factor: 2.4; ranked Q1 in Health Policy; 4 citations;)
4. Arbel, R., Hammerman, A., & Azuri, J. (2018). Usefulness of empagliflozin versus liraglutide for prevention of cardiovascular mortality. American Journal of Cardiology 122, 981-984.
(Impact Factor: 3.2; Ranked Q1 in Cardiology; 3 citations).
5. Arbel, R., Hammerman, A., & Azuri, J. (2018). Usefulness of Ezetimibe Versus Evolocumab as Add-on Therapy for Secondary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiology 123 (8), 1273-1276.
(Impact Factor: 3.2; Ranked Q1 in Cardiology, 2 citations).
6. Arbel, R., Sergienko R., Hammerman, A., Greenberg-Dotan, S, Batat E., Avnery O., & Ellis, MH. (2019). Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. American Journal of Medicine 132(7):847-855.
(IF: 5.1; Ranked Q1 in Medicine, 5 citations).
7. Arbel, R., Sergienko R., Hammerman, A., Greenberg-Dotan, S, Batat E., Avnery O., Greenberg, D. & Ellis, MH. (2019) Direct anticoagulation and mortality in atrial fibrillation. Heart 105(19):1487-1492. (IF: 5.1; Ranked Q1 in Cardiology).